A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment.

Graft-versus-host disease. Lancet (2009) 8.78

A biomarker panel for acute graft-versus-host disease. Blood (2008) 3.83

Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood (2009) 2.16

Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood (2008) 1.39

Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant (2009) 0.97

Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol (2008) 0.95

Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica (2015) 0.94

Plasma biomarkers in graft-versus-host disease: a new era? Biol Blood Marrow Transplant (2009) 0.91

Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res (2013) 0.87

Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease. Expert Opin Pharmacother (2008) 0.87

Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant (2009) 0.85

Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica (2011) 0.84

Graft-versus-host disease: state of the science. Biol Blood Marrow Transplant (2012) 0.84

Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD. Bone Marrow Transplant (2010) 0.82

Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells. Curr Top Microbiol Immunol (2010) 0.81

Overview of T-cell depletion in haploidentical stem cell transplantation. Blood Transfus (2012) 0.78

Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease. Clin Pharmacokinet (2007) 0.78

Gamma irradiation preserves immunosuppressive potential and inhibits clonogenic capacity of human bone marrow-derived mesenchymal stromal cells. J Cell Mol Med (2014) 0.76

Tissue tolerance: a distinct concept to control acute GVHD severity. Blood (2017) 0.75

Regional intra-arterial steroid treatment in 120 patients with steroid-resistant or -dependent GvHD. Bone Marrow Transplant (2017) 0.75

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91

Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics (1990) 10.19

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood (2000) 9.60

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59

The continuing HIV epidemic among men who have sex with men. Am J Public Health (2001) 5.56

All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65

Human general transcription factor IIH phosphorylates the C-terminal domain of RNA polymerase II. Nature (1992) 4.63

Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 4.45

Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11

Bone marrow transplantation for sickle cell disease. N Engl J Med (1996) 4.02

Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med (2001) 3.98

Why outcome of cardiopulmonary resuscitation in general wards is poor. Lancet (1982) 3.71

Definition of a common leukocyte cell-surface antigen (Lp95-150) associated with diverse cell-mediated immune functions. J Immunol (1983) 3.70

A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med (1994) 3.61

Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59

Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J Exp Med (1985) 3.48

Bone-marrow transplantation (first of two parts). N Engl J Med (1975) 3.33

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med (1986) 3.22

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med (1993) 3.18

Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood (1996) 3.12

Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood (1998) 3.06

Identification of a human T lymphocyte surface protein associated with the E-rosette receptor. J Exp Med (1981) 3.06

Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03

Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97

Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc (1974) 2.95

Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A (1990) 2.88

Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med (1993) 2.85

A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood (1995) 2.83

Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood (1997) 2.82

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood (2000) 2.82

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood (1998) 2.76

The canine major histocompatibility complex. Supertypic specificities defined by the primed lymphocyte test (PLT). Immunogenetics (1984) 2.72

Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med (1993) 2.71

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71

Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med (1990) 2.66

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med (1981) 2.61

Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med (1989) 2.61

Percutaneous transluminal coronary angioplasty: report from the Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol (1982) 2.54

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 2.53

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood (2001) 2.52

Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med (1989) 2.42

Cell surface antigens of human melanoma identified by monoclonal antibody. Proc Natl Acad Sci U S A (1979) 2.40

One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36

Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS). Circulation (1981) 2.36

Risk factors for transmission of Mycobacterium tuberculosis in a primary school outbreak: lack of racial difference in susceptibility to infection. Am J Epidemiol (1994) 2.34

A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood (1990) 2.32

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood (1999) 2.31

Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood (1996) 2.30

Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med (1985) 2.30

Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29

Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol (1988) 2.24

Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology (1984) 2.19

Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med (1988) 2.19

A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood (1998) 2.17

Monoclonal antibody analysis of human T lymphocyte subpopulations exhibiting autologous mixed lymphocyte reaction. Proc Natl Acad Sci U S A (1981) 2.16

Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14

The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1. J Immunol (1985) 2.14

Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50. J Immunol (1983) 2.13

A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11

Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant (2001) 2.10

Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood (1990) 2.09

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood (1996) 2.06

A test of the National Death Index using the Coronary Artery Surgery Study (CASS). Control Clin Trials (1985) 2.06

Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood (1999) 1.99

Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood (1994) 1.98

Reiter's syndrome. Evaluation of preliminary criteria for definite disease. Arthritis Rheum (1981) 1.97

A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J Immunol (1986) 1.95

Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology (1998) 1.92

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92

Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med (1993) 1.92

Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol (1990) 1.91

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 1.90

Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med (1983) 1.89

Nomenclature for factors of the HLA system, 2002. Tissue Antigens (2002) 1.89

Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol (1986) 1.89

Circulating Borrelia burgdorferi in patients with acute Lyme disease: results of blood cultures and serum DNA analysis. J Infect Dis (1993) 1.88

The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients. Gastroenterology (1980) 1.88

Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood (1988) 1.86

Esophageal infections: risk factors, presentation, diagnosis, and treatment. Gastroenterology (1994) 1.86